Our science

Publications and presentations

Filter content:

X-Linked Retinitis Pigmentosa

Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (SKYLINE): 24-Month Interim Safety Results

15 October 2024

Subretinal Gene Therapy Drug AGTC-501 for XLinked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (HORIZON): 36-Month Interim Results

19 September 2024

Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Phase 2 SKYLINE Trial

8 February 2024

Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Phase 2 Randomized, Controlled, Multicenter Clinical Trial (Skyline) 3-Month Results

3 December 2023